Probi has received approval from the Thai FDA for the bacterial strain Lactiplantibacillus plantarum HEAL9™. This provides Probi the opportunity to launch the Probi Osteo and Probi Defendum
concepts on the expansive Thai market.
After a two-year process, Probi has also had HEAL9™ approved, after HEAL19™ was approved in autumn 2022 by the Thai FDA. Both probiotic strains are included in Probi’s concepts Probi Osteo and Probi Defendum. The plan is now to launch both concepts in the Thai market within the next 12 months.
Thailand is one of the largest markets for probiotics in the region and therefore a priority market to grow in APAC. Probi already has a small sale of Probi Digestis® in Thailand, but this provides opportunities to grow in more health areas.
“This is an important step for us and shows how we are systematically working to expand our sales in APAC. Thailand is still a fairly small market for us, but with more concepts, we create greater interest in our entire product portfolio and give us the conditions to grow in the entire region,” says Karen Ong, Head of Asia-Pacific, Probi.
ABOUT PROBI
Probi® is a global company focused exclusively on researching, manufacturing, and delivering probiotics for supplements and functional food. We are experts at managing stable, live bacteria from R&D through every stage of the manufacturing process, and are dedicated to making the health-enhancing benefits of probiotics available to people everywhere. Since our founding in 1991 at Sweden’s Lund University, Probi has expanded its operations to more than 40 markets. We hold more than 400 patents globally. Probi had sales of SEK 618 m in 2022. Probi’s shares are listed on Nasdaq Stockholm, Mid-cap, and there were around 3,700 shareholders on December 31, 2022. Read more at www.probi.com.
